Perception Neuroscience

Perception Neuroscience is a subsidiary of atai that is developing arketamine therapy for neuropsychiatric diseases.

Perception Neuroscience

“Perception Neuroscience, an ATAI Life Sciences company, is a biopharmaceutical company developing arketamine therapy for neuropsychiatric diseases. Perception’s mission is to provide substantially more effective treatment solutions to serious psychiatric disorders.”

“Perception Neuroscience’s lead product is the NMDA antagonist arketamine (PCN 101), a single isomer of ketamine.”